MDCO-216: Development discontinued

The Medicines Co. said it will discontinue development of MDCO-216 after it failed to show efficacy at reducing intracoronary atherosclerotic plaque burden in the double-blind, placebo-controlled, international Phase I/II MILANO-PILOT trial. MILANO-PILOT was evaluating 20 mg/kg IV MDCO-216 weekly for 5 weeks in 120 patients with acute coronary syndrome (ACS)...